LEH closes seed investment in Bimini Biotech

 Leiden, 15 October 2021 – LEH invests €250,000 into BIMINI Biotech, an innovative therapeutics start-up that develops new cancer drugs. BIMINI Biotech will leverage the funds to initiate a research program together with The Leiden Academic Centre for Drug Research (LACDR). BIMINI’s technology is based on pioneering research by Professor Ger Strous at UMC Utrecht and has shown promising results in the preclinical phase. The company leverages the growth hormone receptor (GHR) via a unique mode-of-action to inhibit cancer cell growth. BIMINI moved to Leiden in 2020 to continue preclinical research.

BIMINI Biotech